Loading patent…
AssigneesCentro Nacional De Investigaciones Cardiovasculares Carlos III (F.S.P.), Consejo Superior de Investigaciones Cientificas, Universidad Autonoma De Madrid
InventorsJuan Miguel Redondo Moya, Nerea Méndez-Barbero, Jorge Oller Pedrosa, Miguel Ramón Campanero Garcia
Estimating the term…
The present invention refers to an In vitro method for screening for subjects at risk of developing thoracic aortic aneurysm (TAA) or a disease causing TAA comprising: (a) measuring the expression pattern or level of at least A Disintegrin And Metalloproteinase with Thrombospondin Motifs 1 (ADAMTS1) obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least ADAMTS1 of the subjects to be screened with an already established expression pattern or level, wherein reduced expression of at least ADAMTS1 is indicative of a thoracic aortic aneurysm (TAA).
A method for therapeutic treatment of a thoracic aortic aneurysm (TAA) in a patient in need thereof, comprising administering a composition comprising an iNOS inhibitor to the patient, wherein the iNOS inhibitor is selected from the group consisting of 1400W, L-NAME, GW274150, GW273629, Aminoguanidine (AG) hydrochloride L-NIL and clotrimazale.
Dependencies are inferred from the claim text.